4/2/2019 7:11:26 AM
Wedbush Is Cutting SUTRO BIOPHARMA INC (STRO) Q4 19 Rev. Estimate To 11.3 M From 23.8 M
4/2/2019 7:11:13 AM
Wedbush Is Cutting SUTRO BIOPHARMA INC (STRO) Q3 19 Rev. Estimate To 11.3 M From 13.8 M
4/2/2019 7:11:00 AM
Wedbush Is Increasing SUTRO BIOPHARMA INC (STRO) Q2 19 Rev. Estimate To 11.3 M From 3.8 M
4/2/2019 7:10:51 AM
Wedbush Is Increasing SUTRO BIOPHARMA INC (STRO) Q1 19 Rev. Estimate To 11.3 M From 3.8 M
4/2/2019 7:10:27 AM
Wedbush Is Cutting SUTRO BIOPHARMA INC (STRO) FY19 Estimate To -2.34 From -1.89
4/2/2019 7:10:15 AM
Wedbush Is Cutting SUTRO BIOPHARMA INC (STRO) Q4 19 Estimate To -0.62 From -0.01
4/2/2019 7:09:57 AM
Wedbush Is Lowering SUTRO BIOPHARMA INC (STRO) Q3 19 Estimate To -0.56 From -0.33
4/2/2019 7:09:43 AM
Wedbush Is Increasing SUTRO BIOPHARMA INC (STRO) Q2 19 Estimate To -0.61 From -0.80
4/2/2019 7:09:30 AM
Wedbush Is Raising SUTRO BIOPHARMA INC (STRO) Q1 19 Estimate To -0.55 From -0.76
4/2/2019 7:09:00 AM
Wedbush Reiterates SUTRO BIOPHARMA INC (STRO) At Outperform With $22 Price Target
4/1/2019 5:05:50 AM
Sutro Biopharma FY Revenue $38.4 Mln, Net Loss $35.3 Mln
3/15/2019 7:03:08 AM
Sutro Biopharma Initiates Phase I Clinical Trial Of STRO-002 For Ovarian And Endometrial Cancers
3/4/2019 6:57:52 AM
Wedbush Reiterates SUTRO BIOPHARMA INC (STRO) At Outperform With $22 Up From $20 Price Target
1/29/2019 7:11:04 AM
Sutro Biopharma Appoints Andreas Maderna VP Of Chemistry
11/13/2018 7:45:38 AM
Sutro Announces IND Submission And Conclusion Of 30-Day Review Period For STRO-002
10/22/2018 6:23:24 AM
Wedbush Initiates SUTRO BIOPHARMA INC (STRO) At Outperform With $20 Price Target